Skip to content
Biotechnology, Medical Health Aged Care

Study on the safety of Elixinol Hemp Extract is published in Journal of Toxicology

IR Department 2 mins read
Hemp seeds

Elixinol Wellness Limited (ASX: EXL) continues to be a pioneer in the global hemp industry, with the release of a new paper into the safety of Elixinol Hemp Extract in leading scientific publication, Journal of Toxicology.

The paper, entitled “Safety of Elixinol Hemp Extract: In VitroGenetic Toxicity and Subchronic Toxicity in Rat”, reports on safety studies of Elixinol Hemp Extract in rats and concludes that the Extract is safe to use and does not have any adverse effects at the highest dose tested. The paper also suggests that the Elixinol Hemp Extract may have some benefits for human health, with additional studies needed to confirm this.

Elixinol Group CEO and Managing Director, Ron Dufficy, said: “The positive safety results, now published in a well-respected scientific journal, stand Elixinol Hemp Extract and Elixinol more broadly in good stead for the future of our hemp products and offerings.”

Elixinol Hemp Extract contains a blend of hemp extract, cannabidiol (CBD) isolate, and copaiba. CBD is a compound that comes from the cannabis plant and copaiba is a resin that comes from a tropical tree and has anti-inflammatory properties.

The paper details two studies that tested the effects of the Elixinol Hemp Extract on rats. The first study was a short-term 15-day study and the second was a long-term 90-day study. The study found that the Extract did not cause any harmful effects on the rats. It did note some changes in the rats’ liver cells and liver weight, however these changes were not serious and did not affect the liver function. The changes also reversed once the Extract was stopped. 

The paper concludes, “The results from the present studies indicate that Elixinol Hemp Extract is well tolerated in male and female Sprague–Dawley rats and this information contributes to the growing amount of safety information available for hemp extracts and specifically highlights the safety profile of Elixinol Hemp Extract.”

The full paper can be accessed via this link: https://www.hindawi.com/journals/jt/2023/5982883/


About us:

Elixinol Wellness Limited (ASX: EXL) is a pioneer in the global hemp industry, innovating, marketing, and selling hemp and other plant-derived food, skincare, and nutraceutical products:

In Australia, Elixinol Wellness operates a vertically integrated business which produces, manufactures, and distributes a range of highly complementary products delivered across four verticals – human nutrition, human wellness, pet wellness and superfood ingredients. We help our customers feel better by providing delicious, nutritious, and convenient health products, which improve and enrich our customers' lives. These products are sold under brands including Hemp Foods Australia, Mt Elephant and Field Day and are sold through grocery, wholesale, and e-commerce channels. The Australian Superfood Co supplies Australian natives and superfood ingredients to white label customers as well as food, beverage, and beauty manufacturers.

In the Americas, innovating, marketing, and selling high quality Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, USA.

In the United Kingdom, Japan, Brazil, Mexico and South Africa, branded hemp and other plant-derived products are available to consumers via exclusive distribution and/or trademark and know-how licensing agreements.

See more at www.elixinolwellness.com


Contact details:

Cherie Hartley

IR Department

cherie.hartley@irdepartment.com.au

Media

More from this category

  • Government NSW, Medical Health Aged Care
  • 12/07/2024
  • 12:39
MEDIA RELEASE - Network of Alcohol & Other Drug Agencies

NSW DRUG SUMMIT IS AN OPPORTUNITY TO SHELVE OUTDATED POLICIES

12 July 2024 The forthcoming NSW Drug Summit is an opportunity to shelve outdated drug policies that have failed to deliver better health andwellbeing outcomes for individuals and their families. That’s the verdict from the peak organisation for the non-government drug and alcohol sector in NSW, the Network of Alcohol and other Drugs Agencies (NADA). NADA today welcomed the Government’s confirmation the NSW Drug Summit will be held over two days in regional NSW in October, and in Sydney on 4th and 5th December, as well as consultations about the Terms of Reference and other matters ahead of this. NADA…

  • Contains:
  • Medical Health Aged Care
  • 12/07/2024
  • 09:00
National Hypertension Taskforce - Australian Cardiovascular Alliance and Hypertension Australia

Australian Hypertension Taskforce unveils Roadmap to transform high blood pressure control and reduce preventable deaths

Raised blood pressure (BP), also known as hypertension, is a ‘silent killer’ and the leading cause of death in Australia, where it contributes to more than 25,000 deaths each year. It is also the leading risk factor for death from stroke, heart disease, kidney disease, and dementia, yet 68% of Australians with hypertension are uncontrolled. In response to this pressing issue, a Call to Action was published in 2022, leading to the establishment of the National Hypertension Taskforce, launched by Mark Butler MP, Minister for Health and Aged Care. The National Hypertension Taskforce, led by the Australian Cardiovascular Alliance and…

  • Medical Health Aged Care
  • 12/07/2024
  • 00:11
AI Medi Scan

AI Medi Scan Introduces New At-Home Skin Cancer Detection Technology

AI Medi Scan is developing a device that uses artificial intelligence (AI) and fluorescence imaging to allow Australians to conduct skin cancer checks at home, aiming to alleviate the impact of dermatologist shortages.SYDNEY, July 12, 2024 (GLOBE NEWSWIRE) -- AI Medi Scan, an Australian company, is pioneering a shift in skin cancer detection with its ongoing development of advanced diagnostic technologies. Aimed at empowering individuals and integrating with broader healthcare services, AI Medi Scan's long-term goal is to revolutionise how Australians address skin health, particularly in detecting melanoma, a prevalent cancer in the region.The company's current R&D efforts are focused…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.